---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-281199"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:07:16.150220+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IO Biotech reports Q3 net loss $15.7M; Phase 3 melanoma trial site activation accelerates; cash $151.2M

## Summary
- Net loss $15.7M (vs $4.5M in Q3 2021); R&D expenses $10.0M (up from $4.1M) driven by Phase 3 trial costs.
- Cash $151.2M as of Sep 30, 2022 (down from $211.5M at Dec 31, 2021); expected to fund operations into mid-2024.
- Phase 3 trial site activation accelerated: 55 sites actively enrolling (up from 19 at end of July 2022).
- Updated Phase 1/2 data: median OS 46.8 mo, median PFS 22.5 mo, complete response rate 50% in PD-1 naive patients.
- Named Amy Sullivan as CFO in October 2022; new clinical collaboration with Merck for neoadjuvant/adjuvant trial.

## SEC filing metadata
- accession: 0001193125-22-281199
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312522281199/0001193125-22-281199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312522281199/d412247d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-281199
- JSON: https://secwatch.observer/filing/0001193125-22-281199.json
- Plain text: https://secwatch.observer/filing/0001193125-22-281199.txt

## Key facts
- Earnings Releases
  IO Biotech, Inc. reported third quarter ended September 30, 2022 results: net income $15.7 million.
  - Period: third quarter ended September 30, 2022
  - Net income: $15.7 million
  - Result: reported results
  source text: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced today financial results for the quarter ending September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312522281199/0001193125-22-281199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.